Drug class profile · refreshed daily from federal data

Tetracycline-class Drug

3 molecules in this class, $147.0M combined CY2024 Part D spend across 10.9M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Tetracycline-class Drug class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $147.0Mcombined across class
Total Rx claims: 10.9M7.8M unique beneficiaries
Generic mfrs (active): 60across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Doxycycline Hyclate

Brand: Acticlate · 10.4M Part D claims (CY24) · 7.6M beneficiaries · First FDA approval: 1984-05-07

34 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.095

→

Avg plan cost$0.718

Part D spend $131.1M 8× spread, current vs floor

Class share

89%

of class CY24 spend

View profile →

Minocycline

Brand: AMZEEQ · 522K Part D claims (CY24) · 257K beneficiaries · First FDA approval: 1992-02-01

11 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.181

→

Avg plan cost$0.577

Part D spend $15.9M 3× spread, current vs floor

Class share

11%

of class CY24 spend

View profile →

Doxycycline

Brand: Doxy 100 · 27 Part D claims (CY24) · 22 beneficiaries · First FDA approval: 1989-12-29

15 generic mfrs 68 plans require PA

Low NADAC$0.112

→

Avg plan cost$1.29

Part D spend $4756 12× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.